US-based healthcare analytics technology developer OM1 has secured $15m in a series A round featuring Wanxiang Healthcare Investments, a strategic investment subsidiary of auto parts producer Wanxiang.
Venture capital firm General Catalyst led the round, which included Glikvest and healthcare-focused VC fund 7wire Ventures.
OM1’s software provides outcomes measurement and predictive analytics for clinical data to help users best determine individual treatments and improve efficiency. It will use the series A capital to further build out the platform.
Rich Gliklich, founder and chief executive of OM1, said: “The system that we are building at OM1 will give providers unprecedented insight on the relationship between care and outcomes, helping them to avoid high cost events and ultimately provide the best care possible.
“At the same time, we are focused on helping researchers and payers to more quickly and accurately generate real-world evidence and better understand the connection between outcomes and value.”